147 related articles for article (PubMed ID: 26471877)
21. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
22. In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.
Gadhe CG; Balupuri A; Cho SJ
J Biomol Struct Dyn; 2015; 33(11):2491-510. PubMed ID: 25617117
[TBL] [Abstract][Full Text] [Related]
23. Activation of transcription factors STAT1 and STAT5 in the mouse median eminence after systemic ciliary neurotrophic factor administration.
Severi I; Senzacqua M; Mondini E; Fazioli F; Cinti S; Giordano A
Brain Res; 2015 Oct; 1622():217-29. PubMed ID: 26133794
[TBL] [Abstract][Full Text] [Related]
24. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
[TBL] [Abstract][Full Text] [Related]
25. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
26. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening.
Liu LJ; Leung KH; Chan DS; Wang YT; Ma DL; Leung CH
Cell Death Dis; 2014 Jun; 5(6):e1293. PubMed ID: 24922077
[TBL] [Abstract][Full Text] [Related]
27. Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors.
Mitra S; Dash R
J Mol Graph Model; 2018 Aug; 83():42-52. PubMed ID: 29758466
[TBL] [Abstract][Full Text] [Related]
28. Physical and functional interactions between STAT5 and Runx transcription factors.
Ogawa S; Satake M; Ikuta K
J Biochem; 2008 May; 143(5):695-709. PubMed ID: 18296717
[TBL] [Abstract][Full Text] [Related]
29. Chemical probes that competitively and selectively inhibit Stat3 activation.
Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
[TBL] [Abstract][Full Text] [Related]
30. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
31. Nanomolar inhibitors of the transcription factor STAT5b with high selectivity over STAT5a.
Elumalai N; Berg A; Natarajan K; Scharow A; Berg T
Angew Chem Int Ed Engl; 2015 Apr; 54(16):4758-63. PubMed ID: 25702814
[TBL] [Abstract][Full Text] [Related]
32. PPARgamma ligand-dependent induction of STAT1, STAT5A, and STAT5B during adipogenesis.
Stephens JM; Morrison RF; Wu Z; Farmer SR
Biochem Biophys Res Commun; 1999 Aug; 262(1):216-22. PubMed ID: 10448095
[TBL] [Abstract][Full Text] [Related]
33. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains.
Valgeirsdóttir S; Paukku K; Silvennoinen O; Heldin CH; Claesson-Welsh L
Oncogene; 1998 Jan; 16(4):505-15. PubMed ID: 9484840
[TBL] [Abstract][Full Text] [Related]
34. Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy.
Chen HH; Chou CY; Wu YH; Hsueh WT; Hsu CH; Guo HR; Lee WY; Su WC
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):658-66. PubMed ID: 21300446
[TBL] [Abstract][Full Text] [Related]
35. Identification of the structural features that mediate binding specificity in the recognition of STAT proteins by dual-specificity phosphatases.
Jardin C; Sticht H
J Biomol Struct Dyn; 2012; 29(4):777-92. PubMed ID: 22208278
[TBL] [Abstract][Full Text] [Related]
36. Characterization and cloning of STAT5 from IM-9 cells and its activation by growth hormone.
Silva CM; Lu H; Day RN
Mol Endocrinol; 1996 May; 10(5):508-18. PubMed ID: 8732682
[TBL] [Abstract][Full Text] [Related]
37. Differential activation of the STAT pathway by angiotensin II via angiotensin type 1 and type 2 receptors in cultured human fetal mesangial cells.
Seebach FA; Welte T; Fu XY; Block LH; Kashgarian M
Exp Mol Pathol; 2001 Jun; 70(3):265-73. PubMed ID: 11418005
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.
Widschwendter A; Tonko-Geymayer S; Welte T; Daxenbichler G; Marth C; Doppler W
Clin Cancer Res; 2002 Oct; 8(10):3065-74. PubMed ID: 12374673
[TBL] [Abstract][Full Text] [Related]
39. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
40. Blocking the interaction between HIV-1 integrase and human LEDGF/p75: mutational studies, virtual screening and molecular dynamics simulations.
Reddy KK; Singh P; Singh SK
Mol Biosyst; 2014 Mar; 10(3):526-36. PubMed ID: 24389668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
